Biodegradable hybrid-structured nanofibrous membrane supported chemoprotective gene therapy enhances chemotherapy tolerance and efficacy in malignant glioma rats

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Artificial Cells Nanomedicine and Biotechnology

• Publication date

  2018-04-16

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.1080/21691401.2018.1460374PMID 29658349
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Core/shell PLGA microspheres with controllable in vivo release profile via rational core phase design

  2018cited by this paper
• Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment

  2018cited by this paper
• Toxicity, pharmacokinetics, and in vivo efficacy of biotinylated chitosan surface-modified PLGA nanoparticles for tumor therapy

  2017cited by this paper
• An update on applications of nanostructured drug delivery systems in cancer therapy: a review

  2017cited by this paper
• Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes

  2017cited by this paper
• Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes

  2016cited by this paper
• Drug delivery approaches for the treatment of glioblastoma multiforme

  2016cited by this paper
• Concurrent Chemotherapy of Malignant Glioma in Rats by Using Multidrug-Loaded Biodegradable Nanofibrous Membranes

  2016cited by this paper
• Dual delivery of active antibactericidal agents and bone morphogenetic protein at sustainable high concentrations using biodegradable sheath-core-structured drug-eluting nanofibers

  2016cited by this paper
• Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: In vitro and in vivo studies.

  2015cited by this paper
• Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.

  2014cited by this paper
• Chemotherapy for Malignant Gliomas

  2014cited by this paper
• Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

  2013cited by this paper
• Sustainable release of carmustine from biodegradable poly[(d,l)-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies

  2013cited by this paper
• STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression

  2012cited by this paper
• Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.

  2011cited by this paper
• Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence

  2011cited by this paper
• Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors.

  2011cited by this paper
• Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas

  2010cited by this paper
• The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier.

  2009cited by this paper
• Experience with irinotecan for the treatment of malignant glioma.

  2009cited by this paper
• Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

  2009influential reference
• Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

  2009cited by this paper
• Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme

  2009cited by this paper
• Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

  2009cited by this paper
• Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

  2009cited by this paper
• Polymeric nanoparticles for the drug delivery to the central nervous system

  2008cited by this paper
• Intravascular Delivery of Particulate Systems: Does Geometry Really Matter?

  2008cited by this paper
• Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.

  2007cited by this paper
• Local intracerebral administration of O6-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma

  2007cited by this paper
• Chemoradiotherapy in malignant glioma: standard of care and future directions.

  2007cited by this paper
• Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas

  2007cited by this paper
• The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death.

  2005cited by this paper
• Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

  2004cited by this paper
• A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

  2003cited by this paper
• Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

  2002cited by this paper
• Multifaceted resistance of gliomas to temozolomide.

  2002cited by this paper
• Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.

  2002cited by this paper
• Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

  2000influential reference
• Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

  2000cited by this paper
• O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.

  2000cited by this paper
• Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea

  1997cited by this paper
• Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.

  1996cited by this paper
• Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition.

  1995cited by this paper
• Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.

  1995cited by this paper
• Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas

  1995cited by this paper
• Activity of temozolomide in the treatment of central nervous system tumor xenografts.

  1995cited by this paper
• Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.

  1993cited by this paper
• The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers.

  1992cited by this paper
• Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.

  1991influential reference
• Chemotherapy for malignant gliomas.

  1988cited by this paper

• Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma.

  2024cites this paper
• Advancing Cancer Therapy: Unveiling the Cutting-Edge Potential of Carmustine Nano Carriers for Targeted Treatment

  2024cites this paper
• Recent advances in PLGA-based nanofibers as anticancer drug delivery systems

  2023cites this paper
• Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance

  2022cites this paper
• Recent developments in drug delivery strategies for targeting DNA damage response in glioblastoma.

  2021cites this paper
• Causes of drug resistance and glioblastoma relapses

  2021cites this paper
• Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle

  2021cites this paper
• Role of Polymeric Local Drug Delivery in Multimodal Treatment of Malignant Glioma: A Review

  2021cites this paper
• Inhibition of EMMPRIN by microRNA-124 suppresses the growth, invasion and tumorigenicity of gliomas

  2021cites this paper
• Designing Biodegradable Wafers Based on Poly(L-lactide-co-glycolide) and Poly(glycolide-co-ε-caprolactone) for the Prolonged and Local Release of Idarubicin for the Therapy of Glioblastoma Multiforme

  2020cites this paper
• CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway

  2019cites this paper
• Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier

  2018cites this paper